Increased Failure After Irrigation and Debridement for Acute Hematogenous Periprosthetic Joint Infection.


Journal

The Journal of bone and joint surgery. American volume
ISSN: 1535-1386
Titre abrégé: J Bone Joint Surg Am
Pays: United States
ID NLM: 0014030

Informations de publication

Date de publication:
17 Apr 2019
Historique:
entrez: 18 4 2019
pubmed: 18 4 2019
medline: 22 11 2019
Statut: ppublish

Résumé

Acute periprosthetic joint infection (PJI) is difficult to treat. In this study, we investigated the failure rates of irrigation and debridement (I&D) among patients with acute post-surgical and acute hematogenous PJI, and explored various host and organism-related risk factors that may be associated with treatment failure. We retrospectively reviewed the cases of 199 total joint arthroplasty patients who underwent I&D for acute post-surgical PJI (<3 months postoperatively) and acute hematogenous PJI (≥3 months postoperatively, with abrupt symptoms lasting <3 weeks) at a single center during the period of 2005 to 2016. Only patients meeting the Musculoskeletal Infection Society (MSIS) criteria for PJI were included. Patient demographics, comorbidities, physical examination findings, laboratory results, and organism profile were identified. Treatment failure, as defined by the Delphi criteria, was determined for 1-year follow-up. Primary statistical analysis involved univariate and multivariate regression. The failure rate was 37.7% (75 of 199) at 1 year. Among the patients with acute hematogenous infections, the rate of failure (56%, 29 of 52) was almost 2 times higher than that of patients with acute post-surgical infections (31%, 46 of 147) (adjusted odds ratio [OR], 2.36; 95% confidence interval [CI], 1.16 to 4.81; p = 0.018). Host predictors of failure included prior revision surgery (adjusted OR, 2.55; 95% CI, 1.22 to 5.32; p = 0.013) and a higher Charlson Comorbidity Index (adjusted OR, 1.22; 95% CI, 1.01 to 1.51; p = 0.048). Specific comorbidities associated with failure included chronic obstructive pulmonary disease (p = 0.026), diabetes (p = 0.004), and a history of malignancy (p = 0.005). Patients with polymicrobial infections (adjusted OR, 2.40; 95% CI, 1.10 to 5.20; p = 0.028) were also more likely to experience failure of treatment after I&D. The clinical and laboratory risk factors associated with failure were the presence of intraoperative purulence (p = 0.05), elevated systolic blood pressure (p = 0.05), tachycardia (p = 0.06), and higher serum C-reactive protein level (p = 0.003). This study revealed that I&D is associated with a high rate of failure for patients with an acute hematogenous PJI. The study also identified a number of risk factors for failure. The findings of this study may allow better decision-making by surgeons regarding the surgical management of patients with acute PJI. Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

Sections du résumé

BACKGROUND BACKGROUND
Acute periprosthetic joint infection (PJI) is difficult to treat. In this study, we investigated the failure rates of irrigation and debridement (I&D) among patients with acute post-surgical and acute hematogenous PJI, and explored various host and organism-related risk factors that may be associated with treatment failure.
METHODS METHODS
We retrospectively reviewed the cases of 199 total joint arthroplasty patients who underwent I&D for acute post-surgical PJI (<3 months postoperatively) and acute hematogenous PJI (≥3 months postoperatively, with abrupt symptoms lasting <3 weeks) at a single center during the period of 2005 to 2016. Only patients meeting the Musculoskeletal Infection Society (MSIS) criteria for PJI were included. Patient demographics, comorbidities, physical examination findings, laboratory results, and organism profile were identified. Treatment failure, as defined by the Delphi criteria, was determined for 1-year follow-up. Primary statistical analysis involved univariate and multivariate regression.
RESULTS RESULTS
The failure rate was 37.7% (75 of 199) at 1 year. Among the patients with acute hematogenous infections, the rate of failure (56%, 29 of 52) was almost 2 times higher than that of patients with acute post-surgical infections (31%, 46 of 147) (adjusted odds ratio [OR], 2.36; 95% confidence interval [CI], 1.16 to 4.81; p = 0.018). Host predictors of failure included prior revision surgery (adjusted OR, 2.55; 95% CI, 1.22 to 5.32; p = 0.013) and a higher Charlson Comorbidity Index (adjusted OR, 1.22; 95% CI, 1.01 to 1.51; p = 0.048). Specific comorbidities associated with failure included chronic obstructive pulmonary disease (p = 0.026), diabetes (p = 0.004), and a history of malignancy (p = 0.005). Patients with polymicrobial infections (adjusted OR, 2.40; 95% CI, 1.10 to 5.20; p = 0.028) were also more likely to experience failure of treatment after I&D. The clinical and laboratory risk factors associated with failure were the presence of intraoperative purulence (p = 0.05), elevated systolic blood pressure (p = 0.05), tachycardia (p = 0.06), and higher serum C-reactive protein level (p = 0.003).
CONCLUSIONS CONCLUSIONS
This study revealed that I&D is associated with a high rate of failure for patients with an acute hematogenous PJI. The study also identified a number of risk factors for failure. The findings of this study may allow better decision-making by surgeons regarding the surgical management of patients with acute PJI.
LEVEL OF EVIDENCE METHODS
Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.

Identifiants

pubmed: 30994587
doi: 10.2106/JBJS.18.00381
pii: 00004623-201904170-00005
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

696-703

Auteurs

Noam Shohat (N)

The Rothman Institute at Thomas Jefferson University, Philadelphia, Pennsylvania.
Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.

Karan Goswami (K)

The Rothman Institute at Thomas Jefferson University, Philadelphia, Pennsylvania.

Timothy L Tan (TL)

The Rothman Institute at Thomas Jefferson University, Philadelphia, Pennsylvania.

Yale Fillingham (Y)

The Rothman Institute at Thomas Jefferson University, Philadelphia, Pennsylvania.

Javad Parvizi (J)

The Rothman Institute at Thomas Jefferson University, Philadelphia, Pennsylvania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH